Join PSI at Clinical Trials in Oncology and Rare Diseases Europe!
PSI CRO will be in Munich to discuss how sponsors can maintain predictable delivery in complex oncology and rare disease trials while managing enrollment pressure, operational risk, and global execution demands.
PSI has contributed registrational data to 10% of novel oncology drugs approved by the FDA since 2000, supported 21 oncology drug approvals, and works with more than 10,000 oncology sites across 62 countries. These operational capabilities help sponsors maintain control over timelines and endpoint quality in increasingly complex development programs.
Visit PSI at Booth #12
Meet with the PSI team to discuss oncology and rare disease trial execution strategies, enrollment planning, and how platforms like VISIONAL™ and SYNETIC™ support faster feasibility and site identification decisions.
Attending team members:
- Sylvia Demandewicz
Senior Director, Business Development - Maciej Wos
Project Director
Related resources:
Blog: Practice-changing progress and decisive oncology breakthroughs
Case study: Keeping your pivotal study on track: Adaptability in an oncology trial
Webinar: Designing pivotal ADC trials that actually enroll
White paper: Redefining feasibility in oncology
